[1]Willy PJ, Umesono K, Ong ES, et al. LXR, a nuclear receptor that defines a distinct retinoid response pathway[J]. Genes Dev, 1995, 9(9): 1033-1045.
[2]Auboeuf D, Rieusset J, Fajas L, et al. Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-α in humans: no alteration in adipose tissue of obese and NIDDM patients[J]. Diabetes, 1997, 46(8): 1319-1327.
[3]Chen M, Bradley MN, Beaven SW, et al. Phosphorylation of the liver X receptors[J]. FEBS Lett, 2006, 580(20): 4835-4841.
[4]Joseph SB, Castrillo A, Laffitte BA, et al.Reciprocal regulation of inflammation and lipid metabolism by liver X receptors[J]. Nat Med, 2003, 9(2):213-219.
[5]Calkin AC, Tontonoz P. LXR signaling pathology and atherosclerosis[J].Arterioscler Thromb Vasc Biol, 2010, 30(8):1513-1518.
[6]Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors[J]. Nature,2008,454(7203):470-477.
[7]Oosterveer MH, Grefhorst A,Groen AK,et al. The liver χ receptor: control of cellular lipid homeostasis and beyond: implications for drug design[J]. Prog Lipid Res,2010,49(4):342-352.
[8]Smoak K, Madenspacher J, Jeyaseelan S, et al. Effects of liverχreceptor agonist treatment on pulmonary inflammation and host defense[J]. J Immunol , 2008, 180(5):3305-3312.
[9]Annicotte JS, Schoonjans K, Auwerx J. Expression of the liver X receptor alpha and beta in embryonic and adult mice[J]. Anat Rec A Discov Mol Cell Evol Biol, 2004, 277(2):312-316.
[10]Watanabe Y, Jiang SY, Takabe W, et al. Expression of the LXRalpha protein in human atherosclerotic lesions[J].Arterioscler Thromb Vasc Biol, 2005, 25(3):622-627.
[11]Liu QY, Quinet E, Nambi P. Adipocyte fatty acid-binding protein(aP2), a newly identified LXR target gene, is induced by LXR agonist in human THP-1 cells[J]. Mol Cell Biochem,2007, 302(1-2):203-213.
[12]Crisafulli C, Mazzon E, Paterniti I, et al. Effects of Liver X receptor agonist treatment on signal transduction pathways in acute lung inflammation[J]. Respir Res,2010, 11(1):19-24.
[13]Suzuki J, Ogawa M, Muto S, et al. Novel IkB kinase inhibitors for treatment of nuclear factor- kB -related diseases[J]. Expert Opin Investig Drugs, 2011, 20(3):395-405.
[14]Ghisletti S, Huang W, Jepsen K, et al. Cooperative NCoR/SMRT interaction establish a corepressor-based strategy for integration if inflammatory and anti-inflammatory signaling patnway[J]. Genes Dev, 2009,23(6):681-693.
[15]Kiss E, Popovic Z, Bedke J, et al. Suppression of chronic damage in renal allografts by Liver X receptor (LXR) activation relevant contribution of macrophage LXRα[J]. Am J Pathol, 2011,179(1):92-103.
[16]Wang Y, Moser AH, Shigenaga JK, et al. Downregulation of liver X receptor-alpha in mouse kidney and HK-2 proximal tubular cells by LPS and cytokines[J]. J Lip Res,2005, 46(11):2377-2387.
|